AU2018356441B2 - DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress - Google Patents

DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress Download PDF

Info

Publication number
AU2018356441B2
AU2018356441B2 AU2018356441A AU2018356441A AU2018356441B2 AU 2018356441 B2 AU2018356441 B2 AU 2018356441B2 AU 2018356441 A AU2018356441 A AU 2018356441A AU 2018356441 A AU2018356441 A AU 2018356441A AU 2018356441 B2 AU2018356441 B2 AU 2018356441B2
Authority
AU
Australia
Prior art keywords
dpp3
ser
disease
leu
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018356441A
Other languages
English (en)
Other versions
AU2018356441A1 (en
AU2018356441A9 (en
Inventor
Andreas Bergmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4Teen4 Pharmaceuticals GmbH
Original Assignee
4Teen4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Teen4 Pharmaceuticals GmbH filed Critical 4Teen4 Pharmaceuticals GmbH
Publication of AU2018356441A1 publication Critical patent/AU2018356441A1/en
Application granted granted Critical
Publication of AU2018356441A9 publication Critical patent/AU2018356441A9/en
Publication of AU2018356441B2 publication Critical patent/AU2018356441B2/en
Priority to AU2025201656A priority Critical patent/AU2025201656A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2018356441A 2017-10-25 2018-10-24 DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress Active AU2018356441B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201656A AU2025201656A1 (en) 2017-10-25 2025-03-06 DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17198420.6 2017-10-25
EP17198420 2017-10-25
PCT/EP2018/079197 WO2019081595A2 (en) 2017-10-25 2018-10-24 DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201656A Division AU2025201656A1 (en) 2017-10-25 2025-03-06 DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Publications (3)

Publication Number Publication Date
AU2018356441A1 AU2018356441A1 (en) 2020-04-16
AU2018356441A9 AU2018356441A9 (en) 2024-12-19
AU2018356441B2 true AU2018356441B2 (en) 2024-12-19

Family

ID=60186108

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018356441A Active AU2018356441B2 (en) 2017-10-25 2018-10-24 DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
AU2025201656A Pending AU2025201656A1 (en) 2017-10-25 2025-03-06 DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201656A Pending AU2025201656A1 (en) 2017-10-25 2025-03-06 DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Country Status (13)

Country Link
US (2) US11530276B2 (cg-RX-API-DMAC7.html)
EP (2) EP4527458A3 (cg-RX-API-DMAC7.html)
JP (2) JP7424972B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250111243A (cg-RX-API-DMAC7.html)
CN (2) CN118791621A (cg-RX-API-DMAC7.html)
AU (2) AU2018356441B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006563A2 (cg-RX-API-DMAC7.html)
CA (1) CA3080251A1 (cg-RX-API-DMAC7.html)
IL (1) IL274009B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004271A (cg-RX-API-DMAC7.html)
MY (1) MY202502A (cg-RX-API-DMAC7.html)
SG (1) SG11202002594PA (cg-RX-API-DMAC7.html)
WO (1) WO2019081595A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530276B2 (en) * 2017-10-25 2022-12-20 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
CN113557031A (zh) * 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
EP4552649A3 (en) * 2019-08-30 2025-06-25 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
AU2021228207A1 (en) * 2020-02-27 2022-10-20 4TEEN4 Pharmaceuticals GmbH DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
EP4121763A1 (en) * 2020-03-16 2023-01-25 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
CN120359042A (zh) 2022-12-15 2025-07-22 4Teen4制药有限公司 改善危重病患者肺功能的dpp3抑制剂
CN115804836A (zh) * 2022-12-27 2023-03-17 中国人民解放军海军特色医学中心 一种中枢小分子蛋白dpp3在制备降压药物中的应用
CN120857945A (zh) 2023-03-29 2025-10-28 4Teen4制药有限公司 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005106486A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
US20110319289A1 (en) * 2009-02-13 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Services Molecular-based method of cancer diagnosis and prognosis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001016334A2 (en) 1999-09-01 2001-03-08 Incyte Genomics, Inc. Human hydrolytic enzymes
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1793847A2 (en) 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
JP2006230318A (ja) 2005-02-25 2006-09-07 Maruishi Pharmaceutical Co Ltd 関節リウマチの診断方法
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
EP2414542B1 (en) * 2009-03-30 2017-08-30 Tel HaShomer Medical Research Infrastructure and Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
CA2898596A1 (en) 2013-01-28 2014-07-31 Gabriel GOJON ROMANILLOS Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
US20190145981A1 (en) * 2016-04-21 2019-05-16 Sphingotec Therapeutics Gmbh Methods for determining dpp3 and therapeutic methods
US11530276B2 (en) * 2017-10-25 2022-12-20 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005106486A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
US20110319289A1 (en) * 2009-02-13 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Services Molecular-based method of cancer diagnosis and prognosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMAGA S ET AL: "Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue", EUROPEAN JOURNAL OF CANCER, vol. 34, no. 3, 1 February 1998, pages 399 - 405 *

Also Published As

Publication number Publication date
US20210206876A1 (en) 2021-07-08
CA3080251A1 (en) 2019-05-02
CN118791621A (zh) 2024-10-18
WO2019081595A2 (en) 2019-05-02
KR102835427B1 (ko) 2025-07-21
AU2025201656A1 (en) 2025-03-27
EP4527458A2 (en) 2025-03-26
US11530276B2 (en) 2022-12-20
JP2024041975A (ja) 2024-03-27
EP3700937A2 (en) 2020-09-02
IL274009A (en) 2020-05-31
MY202502A (en) 2024-05-01
MX2020004271A (es) 2020-07-29
IL274009B2 (en) 2025-01-01
BR112020006563A2 (pt) 2020-10-13
KR20200083509A (ko) 2020-07-08
JP7424972B2 (ja) 2024-01-30
AU2018356441A1 (en) 2020-04-16
US20230295344A1 (en) 2023-09-21
EP4527458A3 (en) 2025-07-09
WO2019081595A3 (en) 2019-06-20
SG11202002594PA (en) 2020-04-29
WO2019081595A4 (en) 2019-09-06
RU2020116450A3 (cg-RX-API-DMAC7.html) 2021-12-21
AU2018356441A9 (en) 2024-12-19
KR20250111243A (ko) 2025-07-22
CN111542548A (zh) 2020-08-14
RU2020116450A (ru) 2021-11-25
IL274009B1 (en) 2024-09-01
CN111542548B (zh) 2024-07-30
JP2021500376A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
AU2018356441B2 (en) DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
JP7219737B2 (ja) Ｄｐｐ３の定量方法および治療方法
EP3455371B1 (en) Tissue-specific exosomes as biomarkers
US20200308299A1 (en) Anti-gpc-1 antibody
JP2025063078A (ja) アンジオテンシン受容体アゴニストおよび／またはその前駆体による治療のための治療ガイドおよび／または治療モニタリング
CN115244401A (zh) 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
WO2011003369A1 (zh) 一种新的肿瘤标志物
AU2021237689A1 (en) DPP3 in patients infected with coronavirus
RU2787033C2 (ru) Связывающая dpp3 молекула, направленная на специфические эпитопы dpp3 и связывающаяся с ними, и ее применение для профилактики или лечения заболеваний/острых состояний, которые связаны с окислительным стрессом
HK40119686A (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
HK40033470A (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
HK40033470B (zh) 针对并结合於特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途
WO2024200862A1 (en) Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
CN120359042A (zh) 改善危重病患者肺功能的dpp3抑制剂

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 OCT 2025